2026-03-13

Novamab Announces China Phase Ⅱ Clinical Trial Approval for First-in-Class Inhaled IL-4Rα VHH Antibody LQ036 Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD)

More

2025-12-31

Novamab to present at the 9th BFC Global Healthcare Business Development & Investment Conference

More

2025-12-29

Dr. Wan Yakun, founder of Novamab, has been selected as 2025 Shanghai Oriental Talent

More

2025-11-11

Novamab : The world's first inhaled IL-4R α single domain antibody nebulization solution LQ036 has completed the first phase IIb clinical administration

More

2025-09-28

Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2025

More

2025-05-13

Novamab to Present Phase IIa Clinical Trial Data of LQ036 at ATS 2025

More

2025-04-28

Novamab will present the oral TL1A VHH antibody and long-acting TL1A bispecific antibody at the DDW 2025 conference

More

2025-03-25

Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients

More

2024-12-19

Novamab has been listed on the 2024 Cyzone 100 Future Unicorn List

More

2024-12-13

Dr. Yakun Wan, founder of Novamab, was selected as the “Pearl Leading Talent” of Pudong New Area in 2024

More